Short-Acting GLP-1 Drug Lixisenatide Does Not Improve Arterial Stiffness in Diabetic Kidney Patients | Research

The takeaway

Lixisenatide did not significantly change arterial stiffness or cardio-renal biomarkers compared to placebo in 101 patients with type 2 diabetes and chronic kidney disease over 24 weeks, despite improving blood sugar.

No vascular benefit
Lixisenatide failed to improve arterial stiffness (p=0.38) despite lowering blood sugar in T2D+CKD patients

What the researchers found

Lixisenatide did not significantly change Ao-PWV (9.65 vs 9.96 m/s, p=0.38), albuminuria, or Klotho levels compared to placebo after 24 weeks, despite HbA1c improvement, in T2D patients with CKD.

Why it matters

Understanding why some GLP-1 drugs don't protect the heart and kidneys as well as others helps optimize drug selection for high-risk patients.

How the study worked

Single-center, randomized, double-blind, parallel-group, placebo-controlled trial (ISRCTN97699312) with 101 participants (47 lixisenatide, 43 evaluable placebo) over 24 weeks.

What this study cannot tell us

Single-center, small study. 24 weeks may be too short for vascular remodeling. Lixisenatide is short-acting which limits comparison to longer-acting agents.

How to read the evidence

Small but well-designed RCT (double-blind, placebo-controlled). Negative result informative for GLP-1 drug selection.

When this study was published

Published in 2025.

The bigger picture

This helps explain the "GLP-1 RA heterogeneity" — why short-acting agents like lixisenatide don't provide the cardiovascular benefits seen with longer-acting agents like semaglutide.

Questions still open

Would longer-acting GLP-1 drugs (semaglutide, dulaglutide) improve Ao-PWV in CKD patients?
Is the lack of vascular benefit specific to short-acting GLP-1 agonism?
Should GLP-1 drug selection for CKD patients consider cardiovascular trial data?

Common questions

Does lixisenatide help the heart and kidneys?

This study found it does not improve arterial stiffness or kidney markers in diabetic kidney disease patients. Longer-acting GLP-1 drugs like semaglutide have shown better cardiovascular protection in other trials.

Why do different GLP-1 drugs have different heart effects?

Short-acting GLP-1 drugs (like lixisenatide) have different pharmacokinetic profiles than long-acting ones (like semaglutide). This study suggests the duration of GLP-1 receptor activation matters for vascular benefits.

Read the original research

Effect of lixisenatide on arterial stiffness in people with type 2 diabetes and kidney disease: Results of a randomised controlled trial.

Diabetes, obesity & metabolism

View on PubMed ↗Publisher’s paper ↗

Citation

Fountoulakis, Nikolaos; Pavlou, Panagiotis; Stathi, Dimitra; Goubar, Aicha; Corcillo, Antonella; Flaquer, Maria; Ayis, Salma; Gnudi, Luigi; Karalliedde, Janaka. (2026). Effect of lixisenatide on arterial stiffness in people with type 2 diabetes and kidney disease: Results of a randomised controlled trial.. Diabetes, obesity & metabolism. https://doi.org/10.1111/dom.70481